Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18716626 | 0.82 | GAA (0.39) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL24927595 | 0.79 | GAA (0.53) | NPC1GAAALDH1A1HDAC2DPP4 | |
| SCHEMBL8248045 | 0.77 | ALDH1A1 (0.38) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL18743854 | 0.76 | POLB (0.37) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL18743810 | 0.76 | ALDH1A1 (0.37) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL18743818 | 0.76 | MAPT (0.38) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL24927033 | 0.76 | DPP4 (0.44) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL8248295 | 0.76 | RECQL (0.45) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL13596286 | 0.75 | MAPT (0.39) | SMN1; SMN2NPC1GAAMAPTKDM1A | |
| SCHEMBL10101586 | 0.75 | MAPT (0.39) | SMN1; SMN2NPC1GAAMAPTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4142732-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4143178-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222363-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222483-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226074-A1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | SLC40A1, HAMP, SLC19A1 | SMN1; SMN2 1602/4885NPC1 897/4885GAA 634/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | SMN1; SMN2 2512/4885NPC1 389/4885GAA 1395/4885 |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | SMN1; SMN2 2512/4885NPC1 389/4885GAA 1395/4885 |
| US-20220396562-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | SMN1; SMN2 2512/4885NPC1 389/4885GAA 1395/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | SMN1; SMN2 2381/4885NPC1 2015/4885GAA 1390/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | SMN1; SMN2 4292/4885NPC1 4086/4885GAA 1670/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | SMN1; SMN2 2512/4885NPC1 389/4885GAA 1395/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | SMN1; SMN2 2512/4885NPC1 389/4885GAA 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.